您的位置: 首页 > 农业专利 > 详情页

Phenyldifluoromethyl-substituted prolineamide compound
专利权人:
Astellas Pharma Inc.
发明人:
Nakajima, Yutaka,Imada, Sunao,Yamamoto, Eriko,Tsuchiya, Kazuyuki,Harayama, Yu,Matsumoto, Shunichiro
申请号:
AU2018211735
公开号:
AU2018211735A1
申请日:
2018.01.23
申请国别(地区):
AU
年份:
2019
代理人:
摘要:
[Problem] To provide a compound useful as a cathepsin S inhibitor.[Solution] The present inventors have studied on a compound which has a cathepsin S-inhibiting activity and can be used as an active ingredient for a pharmaceutical composition for preventing and/or treating an autoimmune disease such as systemic lupus erythematosus (SLE) and lupus nephritis, an allergy, or organ, bone marrow or tissue graft rejection. As a result, it has been confirmed that a phenyldifluoromethyl-substituted prolineamide compound according to the present invention has a cathepsin S-inhibiting activity. This confirmation leads to the accomplishment of the present invention. The phenyldifluoromethyl-substituted prolineamide compound according to the present invention has a cathepsin S-inhibiting activity, and can be used as a prophylactic and/or therapeutic agent for an autoimmune disease such as SLE and nephritis, an allergy, or organ, bone marrow or tissue graft rejection.
来源网站:
中国工程科技知识中心
来源网址:
http://www.ckcest.cn/home/

意 见 箱

匿名:登录

个人用户登录

找回密码

第三方账号登录

忘记密码

个人用户注册

必须为有效邮箱
6~16位数字与字母组合
6~16位数字与字母组合
请输入正确的手机号码

信息补充